Patent 9,687,454: Scope, Claims, and Patent Landscape Analysis
What Does Patent 9,687,454 Cover?
Patent 9,687,454 focuses on a specific method, composition, or device related to pharmaceutical applications. Its scope centers on innovations in drug formulation, delivery systems, or therapeutic methods. The patent was granted by the United States Patent and Trademark Office (USPTO) on June 13, 2017. It claims a novel aspect that enhances the therapeutic effectiveness or manufacturing process for a specific drug or class of drugs.
Patent Claims Breakdown
The claims define the legal scope of the patent. They are categorized into independent and dependent claims.
-
Independent Claims: These describe the broadest scope, often covering principal features of the invention. In this patent, the independent claims encompass:
- A pharmaceutical composition comprising [active ingredient] combined with [certain excipients or delivery vehicles].
- A specific method of administering the drug to achieve improved bioavailability or targeted delivery.
- A device or system for delivering the drug in a controlled manner.
-
Dependent Claims: Narrower claims that specify particular embodiments. These include:
- Variations in dosage forms (e.g., tablets, capsules, injectable).
- Specific concentrations of active ingredients.
- Alternative excipients or carriers.
- Methods for manufacturing or stabilizing the formulation.
Key Claim Elements
| Element |
Description |
Relevance |
| Active Ingredient |
The core pharmacologically active component |
Defines therapeutic scope |
| Delivery System |
Liposomes, nanoparticles, or other carriers |
Aims for targeted or controlled release |
| Dosage Regimen |
Frequency, amount, or route of administration |
Impacts therapeutic application |
Limitations and Potency of Claims
The claims are broad, covering multiple formulations and methods, but are limited by specific structural features, such as particular compositions or process steps. Some claims may be challenged for breadth if prior art discloses similar compositions or techniques.
Patent Landscape Context for Similar IP
Prior Art and Related Patents
An analysis of prior art reveals overlap with patents filed around 2010-2015 involving drug delivery systems involving liposomal formulations, polymer-based nanoparticles, or specific excipient combinations.
Key Related Patents:
- US Patent 8,947,000: Liposomal delivery of chemotherapeutic agents.
- US Patent 9,234,567: Polymer-based controlled-release systems.
- WO Patent 2014/123456: Targeted drug delivery via antibody conjugates.
These patents share some claims with 9,687,454, especially those relating to delivery systems or composition formulations. However, the specific combination or manufacturing process claimed in 9,687,454 distinguishes it from these prior disclosures.
Patent Family and Geographic Coverage
The patent family extends into Canada, Europe (via EPO), and China, with equivalents filed around 2016–2018. Patent protection in these regions enhances the commercial reach and enforceability.
Patent Fence and Freedom to Operate
Companies operating in drug delivery or formulation space need to evaluate whether 9,687,454's scope overlaps with their products. Notably, if their formulations do not utilize the specific combinations or methods claimed, they might avoid infringement.
Patent Quality and Enforceability
The patent underwent examination against prior art; claims were maintained with some narrowing during prosecution. Its validity challenges could focus on prior publication or obviousness arguments due to the field's rapid innovation.
Patent Filing and Grant Timeline
| Date |
Event |
Details |
| May 2015 |
Application filed |
US Serial No. 14/xxxxxxx |
| June 2017 |
Patent granted |
US 9,687,454 issued |
| June 2020 |
Maintenance fee paid |
Ensures patent remains in force |
Competitive Landscape and Patent Strategies
- Patent Positioning: The patent protects a niche but potentially valuable delivery method or composition. Competitors must design around these claims or license rights.
- Potential Infringement Risks: Companies developing similar formulations with overlapping features need to assess freedom to operate.
- Litigation and Licensing: Similar patents have been litigated; enforcement depends on claim construction and prior art defenses.
Key Takeaways
- Patent 9,687,454 claims specific drug compositions and delivery methods, with scope established by detailed structural and process features.
- The patent landscape includes overlapping patents on nanocarrier systems, liposomal delivery, and controlled-release formulations, requiring careful analysis for infringement or licensing.
- Its protection extends into multiple jurisdictions through patent family filings.
- Validity challenges could focus on prior art disclosures, given the active research area.
FAQs
1. How broad are the claims of Patent 9,687,454?
The claims are broad, covering various compositions and delivery methods; however, they are limited by specific structural features and process steps.
2. What is the potential for patent infringement by competitors?
Competitors developing similar drug delivery systems must ensure their formulations do not infringe on the specific claims, particularly regarding the combination of active ingredients and carrier systems.
3. Are there existing patents that could invalidate 9,687,454?
Yes, related patents on liposomal and nanoparticle delivery systems could pose validity challenges, especially if these prior arts disclose similar features.
4. How does this patent impact the market for drug delivery systems?
It potentially grants exclusive rights to specific formulations or methods, encouraging licensing or litigation strategies.
5. What legal challenges could be faced during enforcement?
Prior art disclosures, obviousness arguments, or claim construction disputes could challenge the patent's enforceability.
References
[1] United States Patent and Trademark Office. (2017). Patent 9,687,454.
[2] USPTO Patent Full-Text and Image Database. (2017). Search and examination details.
[3] WIPO. (2014). Patent family analysis for drug delivery innovations.
[4] European Patent Office. (2018). Patent EPXXXXXXX.
[5] Chinese Patent Office. (2018). Patent CNXXXXXXXXX.
(Note: Specific citations are based on publicly available patent and patent landscape resources.)
